Quizartinib
MH22CAQ
Phase 2 small_molecule active
Quick answer
Quizartinib for newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML is a Phase 2 program (small_molecule) at AXIM BIOTECHNOLOGIES, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AXIM BIOTECHNOLOGIES, INC.
- Indication
- newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active